INFINITY PHARMACEUTICALS

Infinity Pharmaceuticals is a development stage biopharmaceutical company based in Cambridge, MA. The company has entered into a credit facility for up to $100 million with Deerfield Management.

Infinity's lead development candidate, IPI-145 has demonstrated broad clinical activity and tolerability in the treatment of hematologic malignancies. The credit facility offers Infinity financial flexibility in executing on its strategic objectives including advancing the development of IPI-145 in registration studies.